Among patients with unresectable locally advanced non-small cell lung cancer, 12 months of the anti-PD-L1 antibody durvalumab following platinum-based CRT significantly improved both PFS and OS irrespective of PD-L1 expression before CRT [15, 16]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.